Viability of bacterial enteropathogens in fecal samples in the presence or absence of different types of transport media.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 03 12 2018
revised: 10 06 2019
accepted: 03 07 2019
pubmed: 4 8 2019
medline: 28 2 2020
entrez: 4 8 2019
Statut: ppublish

Résumé

Transport media are recommended to improve the sensitivity of fecal culture, but there are limited published data comparing bacterial viability in feces stored with or without transport media. In this study, recovery of bacteria from culture-positive feces after 7 days of storage was assessed under the following conditions: without transport media (w/oTM); with FecalSwab™ Transport and Preservation Medium (FSTM); and with modified Cary-Blair (mCB). All Shiga toxin-producing E. coli (STEC) positive specimens (n = 23) and ≥97.5% of Salmonella-positive specimens (n = 40) remained positive under all conditions. Campylobacter (n = 41) was isolated from 82.9% of feces stored in mCB, 68.4% in FSTM, and 70.7% w/oTM; Shigella (n = 14) 85.7%, 78.6%, and 78.6%; and Yersinia (n = 16) 93.8%, 87.5%, and 81.3%, respectively (P = 0.076, Cochran's Q). Transport media were not required for STEC or Salmonella. mCB may be better than w/oTM or FSTM for other pathogens, but an evaluation with a larger number of specimens is required.

Identifiants

pubmed: 31375249
pii: S0732-8893(18)30714-4
doi: 10.1016/j.diagmicrobio.2019.07.001
pii:
doi:

Substances chimiques

Culture Media 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114862

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Byron Michael Berenger (BM)

Alberta Provincial Laboratory for Public Health, 3030 Hospital Drive NW, Calgary, AB, Canada T2N 2B3; Alberta Public Laboratories, 3535 Research Rd. NW, Calgary, AB, Canada T2L 2K8; Department of Pathology and Laboratory Medicine, University of Calgary, 3535 Research Rd. NW, Calgary, AB, Canada T2L 2K8. Electronic address: Byron.berenger@albertapubliclabs.ca.

Christina Ferrato (C)

Alberta Provincial Laboratory for Public Health, 3030 Hospital Drive NW, Calgary, AB, Canada T2N 2B3.

Linda Chui (L)

Alberta Provincial Laboratory for Public Health, 3030 Hospital Drive NW, Calgary, AB, Canada T2N 2B3; Department of Laboratory Medicine and Pathology, University of Alberta, 8440-112 Street, Edmonton, AB, Canada T6G 2J2.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH